secwatch.observer — SEC 8-K summary
======================================

Issuer:     Revolution Medicines, Inc. (RVMD)
CIK:        0001628171
Form:       8-K
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0000950170-23-059374
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revolution Medicines Q3 net loss $108.4M; updates on RMC-6236, RMC-6291; EQRx close imminent
--------------------------------------------------------------------------------

- Q3 2023 net loss $108.4M vs $73.3M; revenue $0 vs $3.4M; R&D spend $107.7M (+55%).
- Cash $813.2M; updated FY2023 net loss guidance $385-$415M; cash runway into 2025.
- Promising clinical data for RMC-6236 (RAS MULTI) and RMC-6291 (RAS G12C); Phase 3 plans for NSCLC and PDAC in 2024.
- EQRx acquisition expected to close Nov 2023; all-stock deal, ~55M shares issued, adds ~$1.1B net cash (~$20/share issued).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1628171/000095017023059374/0000950170-23-059374-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1628171/000095017023059374/rvmd-20231106.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-059374

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer